Our in-house dynamo, Claudia Pinzon and the rest of the the talented team at OneMedTV, have been busy compiling a wealth of valuable video content captured at AdvaMed2008. Below, some of that footage. To watch the videos, click the thumbnail or visit OneMedPlace.tv. Veralight: David VanAvermaete from Veralight presents a new approach to non-invasive diabetes screening through earlier detection and complication reduction. Microtransponder: T. Jordan Curnes from Microtransponder talks about a wireless neurostimulation device for chronic pain management. BioControl: BioControl speaks about their latest innovations in the pathogen detection space. Chemica Technologies: Chemica Technologies is a research-oriented, biotechnology-focused company. Mesynthes:…
Author: Global Cancer Consortium
In a move that could accelerate the growth of the Clarient’s biomarker business, the company announced Friday that, with Definiens, it will develop and commercialize tools to help evaluate quantitative biomarkers that predict cancer treatment response. Definiens’ platform uses image analysis algorithms to analyze multi-dimensional image data, regardless of file type, complexity or size. The software can be used to automatically identify and quantify regions of interest within breast, prostate and colon cancer tissue samples. Clarient processes large numbers of tissue samples for both clinical decision-making and drug development. These tissue samples are converted into high-resolution digital images that are…
Critical Care Innovations (CCI), a biotechnology-driven device company, is developing minimally-invasive, site-specific and image-guided cancer management systems. By using ultrasound guidance and visualization technologies, along with its proprietary cryothermal and microencapsulation processes, the company has created a unique, site-specific and controlled release cancer management diagnostic and therapeutic system. The company’s microencapsulated controlled delivery process can deliver, with accuracy, individualized therapeutic and concentrated doses of chemotherapeutics directly into targeted regions of the patient’s cancerous tissue, providing sustained release of drugs. By encapsulating drugs, CCI has improved the effectiveness of chemotherapy, lowering toxicity and virtually eliminating side effects.
BSD Medical, a developer of microwave systems used to treat cancer, has received FDA 510(k) clearance for its MicroThermX-100 Microwave Ablation System (MTX-100). MTX-100 is indicated for use in the ablation of soft tissue. The device provides minimally invasive access to the target tissue and can be used in open surgical as well as in percutaneous ablation procedures. The delivery of microwave energy is controlled using a touch-screen monitor. MTX-100 will compete head-on with RF ablation technologies that require patient grounding pads. The device can be used both by surgeons and interventional radiologists. According to the company, MTX-100 will be…
San Diego Sexual Medicine at Alvarado Hospital, led by physician Irwin Goldstein, attempts to improve sexual health through the prevention, diagnosis, treatment, and rehabilitation of conditions or diseases that involve sexual function. Current areas of research and exploration include: Bicycle Riding: Cardiovascular exercise such as jogging, racket ball, running, swimming and tennis has been associated with decreased prevalence of erectile dysfunction. While bicycle riding is a form of cardiovascular exercise, bicycle riding is associated with an increased prevalence of erectile dysfunction. Diabetes: Diabetes mellitus and metabolic syndrome are common health problems in our society. Men who have these conditions often…
POM Wonderful was founded by Stewart and Lynda Rae Resnick, who purchased a 100-acre pomegranate orchard in 1987. The company launched its namesake juice in 2002. From 2003 to 2006, annual sales climbed from $12 million to $91 million. The company is now the largest grower and distributor of pomegranates and pomegranate juice in the U.S. This must be some seriously profitable juice. Since inception, POM has banked on its health benefits. The company has invested more than $23 million in scientific research to support marketing claims. Packaged in precious containers, the juice sells for +/- $4.50 per16-ounce bottle. We…
HealthTronics has made an unsolicited bid to buy Endocare for $26.9 million in cash. The offer represents a 20% premium over Endocare’s closing stock price on August 6th. HealthTronics’ product portfolio includes lithotripters and surgical lasers for treatment of BPH and stones, and anatomical pathology services. We interviewed HealthTronics’ VP of Business Development, Jeff Howell, in May. His team has been working overtime as of late. In July, HealthTronics acquired UroPath, a U.S. provider of anatomical pathology laboratory services, for $7.5 million. That deal followed the March acquisition of Advanced Medical Partners, Inc. (AMPI), a transaction that has more in…
Not wanting to break a winning streak, Clarient delivered its 16th consecutive quarter of quarterly revenue growth. The company posted revenues of $16.9 million in its most recent quarter, a 71% increase over the same period last year. Based on performance in the first half of 2008, Clarient raised fiscal year 2008 revenue guidance to $62 – $66 million, from guidance of $56 – $60 million. According to the company, the increase in revenues was driven by higher testing volume, a favorable service mix and higher Medicare reimbursement rates. Clarient continues to acquire and retain customers. Testing volumes for the…